The global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs)
Diagnosis plays a critical role in guiding patients towards appropriate and readily available therapies that can enhance their quality of life
Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has extended its partnership with Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs).
Under the renewed one-year partnership agreement, CENTOGENE will continue to provide Takeda with access to diagnostic testing for patients around the world. The aim of the commercial fee-for-service agreement is to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.
https://finance.yahoo.com/news/centogene-extends-strategic-partnership-takeda-103000272.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.